
|Videos|January 18, 2023
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement












